Top Markets
#1 Helium Helium +41.95%
#2 Seeker Seeker +35.56%
#3 TENDIES TENDIES +31.40%
#4 Pons Pons +29.86%
#5 UnifAI Network UnifAI Network +19.14%
#6 Zylo Ecosystem Zylo Ecosystem +16.99%
#7 DAPPOS DAPPOS +16.76%
#8 ZKsync ZKsync +15.63%
#9 Zora Zora +14.87%
#10 pipedog pipedog +14.42%
Coin of the day
Helium Helium
Settings
Language
ENGLISH
Currency
USD
Theme
Climb Bio, Inc. Climb Bio, Inc.

Climb Bio, Inc.

CLYM
Rank in Stocks #10440
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic... Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
Share Price
$14.66
Last synced: 2026-08-28
Market Cap
$839.37M
Change (1 day)
-2.67%
Change (1 year)
557.32%
Country
US
Trade Climb Bio, Inc. (CLYM)

Category

Healthcare
P/E ratio for Climb Bio, Inc. (CLYM)
P/E ratio as of 2026 TTM: 0
According to Climb Bio, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Climb Bio, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.